Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


Last --
Change Today 0.00 / 0.00%
Volume 0.0
4543 On Other Exchanges
Symbol
Exchange
4543 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

terumo corp (4543) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TERUMO CORP (4543)

Related News

No related news articles were found.

terumo corp (4543) Related Businessweek News

No Related Businessweek News Found

terumo corp (4543) Details

Terumo Corporation manufactures and sells medical products and equipment worldwide. The company operates through Cardiac & Vascular, General Hospital, and Blood Management segments. Its cardiac and vascular products primarily comprise interventional devices that include access devices, such as introducer sheaths, guidewires, and guiding catheters; therapeutic devices, which include balloon catheters and stents; intravascular imaging systems; and cardiopulmonary bypass systems comprising oxygenator with integrated arterial filters, heart-lung machines, and artificial thoracic vascular grafts. The company’s general hospital products principally include infusion systems, including infusion pumps, infusion solutions, IV catheter, and infusion line connectors; drug and devices comprising prefilled syringes and prefillable syringes; nutritional supplements; measuring devices systems with communication functions, such as blood glucose meters, blood pressure monitors, and thermometers; pain management medicines that include analgesic and antiemetic; and closed anticancer drug infusion systems. Its blood management products primarily comprise automated blood collection systems, blood bag systems with leukocyte reduction filters, automated blood component processing system, pathogen reduction technology systems, therapeutic apheresis systems, and cell expansion systems. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was founded in 1921 and is headquartered in Tokyo, Japan.

19,934 Employees
Last Reported Date: 06/25/15
Founded in 1921

terumo corp (4543) Top Compensated Officers

Senior Executive Officer, Director, Chief Exe...
Total Annual Compensation: ¥108.0M
Compensation as of Fiscal Year 2015.

terumo corp (4543) Key Developments

Terumo Corporation Revises Earnings Guidance for the Year Ending March 31, 2016

Terumo Corporation revised earnings guidance for the year ending March 31, 2016. For the year, the company now expects net sales of JPY 525,000 million, operating income of JPY 80,000 million, ordinary income of JPY 75,000 million, profit attributable to owners of parent of JPY 50,000 million and EPS of JPY 132.59 against previous forecast of net sales of JPY 525,000 million, operating income of JPY 76,000 million, ordinary income of JPY 73,000 million, profit attributable to owners of parent of JPY 48,500 million and EPS of JPY 128.73.

Terumo Reports Earnings Results for the Third Quarter of 2016; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2016

Terumo reported earnings results for the third quarter of 2016. For the quarter, revenue was JPY 396 billion for a 9% increase. Operating income expanded 21% to JPY 64.1 billion. In ordinary income, the company saw a smaller rate of growth at 4% and this was due to foreign exchange rate impacts. Net income has grown at a CAGR of 17% from JPY 24.2 billion to JPY 38.5 billion, but ROE has only increased slightly from 7.0% to 7.2%. For the year-end, the company maintained guidance of JPY 525 billion in revenue while revising the operating income, ordinary income and net income JPY 4 billion, JPY 2 billion and JPY 1.5 billion, respectively.

Terumo Corporation, Q3 2016 Earnings Call, Feb 04, 2016

Terumo Corporation, Q3 2016 Earnings Call, Feb 04, 2016

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4543:JP ¥3,780.00 JPY -100.00

4543 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $181.44 USD +1.79
Edwards Lifesciences Corp $76.34 USD -0.63
Olympus Corp ¥4,030 JPY -60.00
Smith & Nephew PLC 1,067 GBp +11.00
St Jude Medical Inc $50.45 USD +0.15
View Industry Companies
 

Industry Analysis

4543

Industry Average

Valuation 4543 Industry Range
Price/Earnings 33.5x
Price/Sales 2.9x
Price/Book 2.6x
Price/Cash Flow 31.2x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TERUMO CORP, please visit www.terumo.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.